|
Study
reference | Disease
(number of patients) | Autograft immune effector cells | 2-year overall survival rates | 2-year progression-free survival rates |
|
| Dean et al., 2005 [24] | Diffuse large B-cell lymphoma
(53) | DC 1 ≥ 0.06
0.45 × 109 cells/kg | | 55% |
DC 1 < 0.06
0.45 × 109 cells/kg | | 35% |
| | | () |
|
| Schmidmaier et al., 2008 [25] | Multiple myeloma
(41) | CD4 ≥ 0.45 × 109
cells/kg | | 80% |
CD4 < 0.45 × 109
cells/kg | | 40% |
| | | () |
|
| Porrata et al., 2014 [26] | Diffuse large B-cell lymphoma
(379) | Lymphocyte to monocyte ratio ≥ 1.0 | 85% | 75% |
| Lymphocyte to monocyte ratio < 1.0 | 40% | 30% |
| | () | () |
|
| Porrata et al., 2014 [27] | Hodgkin’s lymphoma
(183) | Lymphocyte to monocyte ratio ≥ 1.0 | 95% | 85% |
| Lymphocyte to monocyte ratio < 1.0 | 60% | 30% |
| | () | () |
|
| Porrata et al., 2015 [28] | T-cell non-Hodgkin’s lymphoma
(109) | Lymphocyte to monocyte ratio ≥ 1.0 | 90% | 80% |
| Lymphocyte to monocyte ratio < 1.0 | 45% | 30% |
| | () | () |
|
| Porrata et al., 2016 [29] | Non-Hodgkin’s lymphoma
(122) | NK ≥ 0.06
0.45 × 109 cells/kg | 85% | 79% |
NK < 0.06
0.45 × 109 cells/kg | 70% | 45% |
| | () | () |
|
